(Reuters) - Cancer drugmaker Geron Corp said it would halt the study of its experimental drug, imetelstat, as a treatment for breast cancer and the drug was also unlikely to move forward in trials for advanced non-small cell lung cancer, causing the company's shares to shed nearly half their value. The company stopped the mid-stage breast cancer trial after an interim check showed that the drug was not better than the current standard of care in extending patients' lives without the disease progressing. ... via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment